Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus salivarius LF01
- Development stage
- Phase 1
- Lead developer
- Guangdong Nanxin Medical Technology
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
LF01 (also known as Lactobacillus salivarius LF01) is an orally administered live biotherapeutic product (LBP) consisting of a proprietary strain of *Lactobacillus salivarius*. Developed by Guangdong Nanxin Medical Technology, LF01 is designed to activate the host immune system to exert anti-tumor effects. Preclinical studies demonstrate that the LF01 strain can adhere to cell surfaces and promote the differentiation of macrophages into the M1 pro-inflammatory phenotype. This activation triggers the secretion of pro-inflammatory cytokines, anti-tumor cytokines, and chemokines, which recruit and activate other immune cells to mount an anti-tumor immune response. LF01 is currently in Phase I clinical development in China for the treatment of advanced malignant solid tumors.
- Other names
- LF-01胶囊LF01 capsulesLF-01 capsulesLF 01 capsulesLF01胶囊唾液乳杆菌LF01
02
Targets
Sucrase-Isomaltase
Beyond the preview
Go deeper on Lactobacillus salivarius LF01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus salivarius LF01.